Login to Your Account



NASH phase Ib winner for Durect; kidney damage bid up next

By Randy Osborne
Staff Writer

Tuesday, November 1, 2016

Durect Corp. CEO James Brown told BioWorld Today that, although phase Ib results proved encouraging with the endogenous, oral small-molecule DUR-928 in patients with NASH, the phase II trial planned for next year will test the drug in acute kidney damage.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription